Compounded HYDROmorphone Syringes Recalled for Lack of Sterility Assurance
Central Admixture Pharmacy Services is recalling 2,228 HYDROmorphone injectables (0.1 mg/mL) due to lack of validation data for sanitization cycles affecting sterility assurance. Multiple lot numbers distributed nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall of an injectable compounded medication where lack of sterility assurance poses inherent patient risk. However, no illnesses, injuries, or hospitalizations have been reported, so per the rubric, the score is capped at 3 for theoretical hazards without confirmed harm.
Plain-English summary
Central Admixture Pharmacy Services Inc is recalling HYDROmorphone in dextrose 5% (3 mg/30 mL, 0.1 mg/mL concentration) supplied in 30 mL syringes. The affected product is an injectable compounded medication with NDC 71286-2013-2. A total of 2,228 syringes from multiple lot numbers have been distributed nationwide.
The recall was initiated due to lack of assurance of sterility. Specifically, there was a lack of validation data for the firm's sanitization cycles used in the compounding process. This validation gap means there is inadequate documentation that the sanitization procedures effectively eliminate microorganisms from equipment used to prepare the medication.
Healthcare providers and facilities that received this product should check their inventory against the affected lot numbers and expiration dates. Any unused product from these lots should be quarantined and not administered to patients. Patients or healthcare providers who believe they may have received a dose from an affected lot should contact their healthcare provider immediately.
The recalled product
- Product
- HYDROmorphone in dextrose 5%, 3 mg/30 mL, (0.1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2013-2
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable Compounded
- Hazard
- sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-270675
- 17-270683
- Exp. 7/18/2023
- 17-271147
- 17-271119
- Exp. 7/25/2023
- 17-271339
- Exp. 7/27/2023
- 17-271679
- Exp. 8/2/2023
- 17-272202
- Exp. 8/10/2023
- 17-272241
- Exp. 8/13/2023
- 17-272375
- Exp. 8/15/2023
- 17-272783
- Exp. 8/22/2023
- 17-273438
- 17-273431
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27